You did state in your opening remarks that we aggressively moved forward and that, as early as March and April, we had invested in vaccine development and the development of therapeutics. However, you did say, and I quote, that these are “not trivial undertakings”.
Could you explain to us what those timelines are in terms of developing these things and elaborate on that particular point for the benefit of our members?